Allie Strickler

Articles

Birrer Assesses Current Challenges in Cervical Cancer

November 21st 2016

Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.

Dreicer Discusses Optimizing Treatment in mCRPC

November 19th 2016

As oncologists await the next major treatment advances in metastatic castration-resistant prostate cancer (mCRPC), the key in the interim is to optimize the available therapies, says Robert Dreicer, MD.

Vokes on Increasing Impact of Immunotherapy in Head and Neck Cancer

November 18th 2016

As immunotherapy continues to make headway in several different cancer types, these agents are only just arriving to the treatment landscape of head and neck cancer.

Expert Anticipates Avalanche of Data to Impact Treatment Landscape in NSCLC

November 18th 2016

Treatment in lung cancer continues to evolve at a rapid pace with the arrival of a set of efficacious new agents and promising evidence-based data. According to Corey J. Langer, MD, a veritable avalanche of additional data is on the way.

Biomarker Development Key to Optimizing Immunotherapy in Lung Cancer

November 17th 2016

The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.

Pembrolizumab Antitumor Activity Promises Potential for Sarcoma Subtypes

November 15th 2016

Pembrolizumab reduced the size of tumors in patients with a subtype of soft tissue sarcoma, according to updated interim results from the phase II SARC028, multicenter clinical trial, which were reported at the most recent meeting of the Connective Tissue Oncology Society in Lisbon, Portugal.

Eribulin Shows Efficacy in Leiomyosarcoma, Further Research Needed

November 3rd 2016

A subgroup analysis from a phase III, open-label, randomized study showed that eribulin had comparable activity to dacarbazine in patients with leiomyosarcoma.

Expert Discusses Promise of Nivolumab in Advanced Bladder Cancer

November 1st 2016

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

First-Line Pembrolizumab Just the Beginning for Novel Approaches in Bladder Cancer

October 27th 2016

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Pegram Excited for Additional Advances in HER2+ Breast Cancer

October 25th 2016

Mark Pegram, MD, sheds light on some of the recent groundbreaking trials in HER2-positive breast cancer and how they have come to shape the current treatment paradigm.

Ribociclib Results Hailed as Practice Changing in HR+ Breast Cancer

October 24th 2016

Gabriel N. Hortobagyi, MD, discusses the MONALEESA-2 trial, in which the addition of the CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival in women with hormone receptor–positive advanced breast cancer.

Niraparib Expected to Change Practice in Ovarian Cancer

October 19th 2016

The PARP1/2 inhibitor niraparib significantly improved progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

Expert Assesses Immunotherapy Advances in Kidney Cancer

October 18th 2016

Immunotherapy is at the forefront of the burgeoning treatment landscape in renal cell carincoma, according to David McDermott, MD.

Mature Data Sustain Frontline OS Benefit of Pembrolizumab in Melanoma

October 17th 2016

A final analysis of the overall survival data from the KEYNOTE-006 trial showed that frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma.

Pembrolizumab Shows Promising Antitumor Activity in Cervical Cancer

September 30th 2016

Pembrolizumab (Keytruda) was well tolerated and demonstrated promising antitumor activity in patients with PD-L1–positive advanced cervical squamous cell cancer.

Study Shows Cervical Cancer Screening Reduces Mortality

September 29th 2016

Regular screening for cervical cancer was found to be associated with an overall mortality prevention rate of 83%.

Study Suggests Superiority of Functional Imaging in Assessing Sarcoma Outcomes

September 26th 2016

A comparison of anatomic and functional imaging in the assessment of clinical outcomes in patients with Ewing sarcoma has shown that FDG-PET, assessed by PERCIST criteria, was superior in predicting clinical benefits and identifying responses.

Vital Molecular Differences Found in Neuroendocrine Tumor Subtypes

September 23rd 2016

A genomic analysis of poorly differentiated neuroendocrine tumors from primary lung and gastrointestinal sites underscores the diversity of these tumors and the evolving need to move toward precision medicine when it comes to treating patients with these malignancies.

Published Results Affirm Efficacy of Fixed-Dose Pembrolizumab in HNSCC

September 22nd 2016

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.